Methiopropamine Stats & Data
CNC(C)Cc1cccs1HPHUWHKFQXTZPS-UHFFFAOYSA-NInteraction Warnings
MPA can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
The neurotoxic effects of MDMA may be increased when combined with amphetamine and other stimulants.
This combination may increase strain on the heart.
Receptor Profile
Receptor Actions
Receptor Binding
History & Culture
1942–present
Methiopropamine was first synthesized and reported in 1942. The work was primarily conducted at the University of Michigan, with limited pharmacological evaluation carried out at Parke Davis pharmaceutical company. This early research demonstrated that the compound possessed substantial pressor (blood pressure-increasing) activity. Following its initial characterization, the substance remained largely obscure for several decades with no significant research attention or recreational interest.
2010–present
Methiopropamine appeared for public sale in the United Kingdom in December 2010, marketed as a "research chemical" or "legal high" and sold in both powder and pill form. One of its earliest brand names was "Blow." The compound's structural resemblance to methamphetamine initially led vendors and users to anticipate stronger recreational properties than the substance could actually deliver. Throughout the 2010s, MPA was marketed under numerous brand names including Ivory Dove Ultra, China White, Walter White, Quick Silver Ultra, Bullet, Mind Melt, Pink Panthers, Poke, Rush, and Snow White. Products labeled as "Synthacaine" contributed to some users expecting cocaine-like effects, though these products were often found to contain additional substances beyond MPA alone. MPA was frequently combined with other novel psychoactive substances and sold as branded blends. Notable products included Sparkle-E (combining MPA with MDAI, later reformulated with 5-MeO-DALT), Pink Panther (MPA with MDAI and other compounds), Green Beans and M&M (both containing MPA with NM2AI), and GoGaine (MPA with MDAI, later reformulated with ephedrine). These formulations evolved over time as manufacturers adjusted their compositions in response to market conditions and regulatory changes. In Scotland, MPA gained particular traction among people who inject drugs, reportedly replacing ethylphenidate as a preferred substance within certain user communities following controls placed on methylphenidate-based novel psychoactive substances.
Subjective Effect Notes
physical: The physical effects of methiopropamine can be broken down into several components which progressively intensify proportional to dosage.
cognitive: The cognitive effects of methiopropamine can be broken down into several components which progressively intensify proportional to dosage. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Effect Profile
Curated + 28 ReportsStrong stimulation, euphoria, focus, and anxiety/jitters
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 28 experience reports (28 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 9
Adverse Effects 9
Real-World Dose Distribution
62K DosesFrom 33 individual dose entries
Insufflated (n=16)
Oral (n=10)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 23 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Australia | Uncontrolled | As of 2018, not specifically scheduled under federal legislation. May still be subject to analog provisions in some states. |
| Austria | Illegal (SMG) | Controlled under the Suchtmittelgesetz (Narcotics Act) since June 26, 2019. Possession, production, and sale are prohibited. |
| Canada | Potentially controlled (analog provisions) | Not specifically scheduled, but may be considered an illicit analog under the Controlled Drugs and Substances Act due to structural similarity to methamphetamine. |
| China | Controlled substance | Added to the list of controlled substances by the China Food and Drug Administration effective October 1, 2015. |
| Finland | Illegal | Classified as an illegal substance under Finnish drug legislation. |
| France | Stupéfiant | Classified as a stupéfiant, the French designation for recognized drugs of abuse with the highest level of control. Possession, purchase, sale, and manufacture are illegal. |
| Germany | Anlage I BtMG | Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited. |
| Switzerland | Verzeichnis D | Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics regulations. |
| United Kingdom | Class B | Initially placed under a Temporary Class Drug Order on November 27, 2015, following recommendation by the Advisory Council on the Misuse of Drugs. After the TCDO demonstrated effectiveness in reducing availability and harm indicators, MPA was permanently added to the Misuse of Drugs Act 1971 as a Class B substance on November 27, 2017. |
| United States | Unscheduled (Federal Analogue Act may apply) | Not scheduled at the federal level. However, the DEA has noted it is a 2-thienyl analog of the Schedule II substance methamphetamine, and prosecution under the Federal Analogue Act is possible if sold for human consumption. The structural differences from methamphetamine (five-member sulfur-containing ring versus benzene ring) make analogue status legally uncertain. State-level controls exist in Florida (Schedule I since December 2012) and Arizona (listed as a dangerous drug since April 2014). |
References
Data Sources
Cited References
- Blicke & Burckhalter (1942) - α-Thienylaminoalkanes
- Bluelight: Methiopropamine Megathread
- Drugs-Forum: Methiopropamine Experiences
- Erowid: Methiopropamine Vault
- Iversen et al. (2013) - Neurochemical profiles of some novel psychoactive substances
- Lee et al. (2014) - Acute toxicity associated with recreational use of methiopropamine
- Tuv et al. (2021) - Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents
- UK Advisory Council on the Misuse of Drugs (2015) - Methiopropamine Review
- WHO Expert Committee on Drug Dependence (2016) - Methiopropamine Critical Review Report